We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

63 hedge funds and large institutions have $91.2M invested in LENZ Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $507K | Put options by funds: $406K

13% more capital invested

Capital invested by funds: $80.7M → $91.2M (+$10.5M)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0% more funds holding

Funds holding: 63 → 63 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

0.17% less ownership

Funds ownership: 7.44% → 7.27% (-0.17%)

Holders
63
Holders Change
–
Holders Change %
0%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
17
Reduced
16
Closed
14
Calls
$507K
Puts
$406K
Net Calls
+$101K
Net Calls Change
+$252K

Top Buyers

1
APM
Avidity Partners Management
Texas
+$2.94M
2
EC
EcoR1 Capital
California
+$1.43M
3
PM
Prosight Management
Texas
+$1.21M
4
PFMU
Privium Fund Management (UK)
United Kingdom
+$750K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$464K

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$2.35M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.21M
3
KPF
K2 Principal Fund
Ontario, Canada
-$1.1M
4
Renaissance Technologies
Renaissance Technologies
New York
-$903K
5
WP
Woodline Partners
California
-$825K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$26.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$15.4M -$1.21M -50,672 -7%
EC
3
EcoR1 Capital
California
$5.01M +$1.43M +59,993 +36%
APM
4
Avidity Partners Management
Texas
$4.99M +$2.94M +123,571 +122%
Citadel Advisors
5
Citadel Advisors
Florida
$4.04M -$156K -6,541 -3%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.81M +$464K +19,482 +13%
TCM
7
Tang Capital Management
California
$3.49M – – –
Federated Hermes
8
Federated Hermes
Pennsylvania
$3.35M +$5.7K +239 +0.2%
BOTOTLSJU
9
Board of Trustees of The Leland Stanford Junior University
California
$2.23M – – –
AG
10
Artal Group
Luxembourg
$2.22M – – –
OM
11
Opaleye Management
Massachusetts
$1.83M +$399K +16,750 +25%
LCM
12
Laurion Capital Management
New York
$1.82M – – –
PFMU
13
Privium Fund Management (UK)
United Kingdom
$1.79M +$750K +31,483 +64%
Renaissance Technologies
14
Renaissance Technologies
New York
$1.66M -$903K -37,904 -34%
BlackRock
15
BlackRock
New York
$1.53M -$17.2K -720 -1%
OMC
16
OUP Management Company
Pennsylvania
$1.29M – – –
PM
17
Prosight Management
Texas
$1.13M +$1.21M +50,921 New
Millennium Management
18
Millennium Management
New York
$1.11M -$598K -25,083 -33%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$844K +$90.9K +3,814 +11%
Two Sigma Investments
20
Two Sigma Investments
New York
$825K -$602K -25,276 -40%
OMC
21
Oasis Management Company
Cayman Islands
$809K – – –
Goldman Sachs
22
Goldman Sachs
New York
$798K -$566K -23,764 -40%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$696K +$211K +8,841 +39%
CAM
24
Cormorant Asset Management
Massachusetts
$633K – – –
GCP
25
GSA Capital Partners
United Kingdom
$605K +$301K +12,621 +86%
1
2 3

LENZ Hedge Fund Activity: Q3 2022 in Review

63 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2022, worth a combined $91.2M — up 13% from $80.7M a quarter earlier.

Fund positioning in LENZ was balanced in Q3 2022: 14 funds opened new positions, 14 closed out, 17 added to existing stakes and 16 trimmed.

The largest buyer was Avidity Partners Management, adding an estimated $2.94M. The largest seller was Morgan Stanley, cutting an estimated $2.35M.

  • 63 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $91.2M of LENZ Therapeutics stock for Q3 2022, up 13% quarter-over-quarter.
  • 14 funds opened new LENZ Therapeutics positions in Q3 2022 and 14 closed out, a net change of 0 holders.
  • The largest LENZ Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $2.94M added.
  • The largest LENZ Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $2.35M sold.

Based on aggregated 13F filings for Q3 2022.